FDA approves Xgeva to treat giant cell tumour of the bone

The US Food and Drug Administration yesterday announced that it has expanded the approved use of Amgen's Xgeva to cover the treatment of giant cell tumour of the bone (GCTB), a rare and usually non-cancerous tumour.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news